Repligen Q3 2026: Record Revenue, Raised Guidance, and a $41.2M Charge

Repligen reported Q3 2026 adjusted EPS of $0.53, beating estimates, with revenue up 10.9% YoY. A $41.2M impairment charge resulted in a GAAP loss of $(0.68). Adjusted margins improved, and guidance was raised to $844M-$852M. The BioLife acquisition is now integrated, adding a cell therapy consumables platform. Risks include tariffs, integration, and currency fluctuations.

Original reporting
Published Oct 27, 2026, 11:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Repligen Q3 2026: Record Revenue, Raised Guidance, and a $41.2M Charge — source image
Decision brief

The 30-second read

$RGENBullishHigh
01

Why it matters

The earnings beat and guidance raise are likely to boost the stock, but the impairment and integration risks may limit the rally.

02

Market read

First‑report earnings with guidance lift; material for traders targeting biotech and small‑cap equities.

03

What to watch

Potential foreign‑currency and tariff exposure from new Seoul training center.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Repligen's Q3 results include a record revenue increase, an impairment charge, and the integration of the BioLife acquisition.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Repligen reported Q3 2026 earnings, beat estimates and raised full-year revenue guidance to $844‑$852M.

Expected impact

likely upward pressure as investors price in higher revenue outlook

Evidence & confidence

Earnings beat combined with a guidance increase typically drives short‑term buying.

Market effects

Bioprocessing consumables sector may see broader optimism from Repligen's guidance lift.

Positive for US biotech equities; limited regional effect.

Modest, as Repligen is a niche player in the global biotech supply chain.

Counterpoint

The $41.2M impairment could signal deeper integration risks, tempering upside.

Key entities

  • Repligen

    Bioprocessing consumables and systems provider.

  • BioLife Solutions

    Recent acquisition now part of Repligen's consumables platform.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.